<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01186705</url>
  </required_header>
  <id_info>
    <org_study_id>10-068</org_study_id>
    <nct_id>NCT01186705</nct_id>
  </id_info>
  <brief_title>Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer</brief_title>
  <official_title>A Phase II Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test a new drug called MK-2206 for metastatic colorectal&#xD;
      cancer. This drug is being tested in a subgroup of patients with colorectal cancer whose&#xD;
      tumors have changes in certain genes that may make them more likely to respond to this new&#xD;
      medication. As tumors develop, the cells within the tumor acquire mutations within genes,&#xD;
      allowing them to grow more effectively. We will be testing your tumor for mutations involving&#xD;
      two genes - KRAS and PIK3CA. Patients whose tumors have a normal copy of the KRAS gene and a&#xD;
      mutation within the PIK3CA gene will be eligible to participate in this study.&#xD;
&#xD;
      This study is a phase 2 study. The goal of a phase 2 study is to find out what effects, good&#xD;
      and/or bad, a new treatment has against a certain type of cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of accrual&#xD;
  </why_stopped>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Objective Response Rate (ORR)</measure>
    <time_frame>1 year</time_frame>
    <description>in patients with metastatic colorectal cancer with known PIK3CA mutations and wild type KRAS, to single agent MK-2206. Response and progression will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Colon Cancer</condition>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>MK-2206</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This will be a single-arm, phase II study of the AKT inhibitor MK-2206 in patients with KRAS-wild-type, PIK3CA-mutated, colorectal cancer whose tumors have progressed through standard chemotherapy regimens.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-2206</intervention_name>
    <description>Patients will receive MK-2206 orally in a once weekly dose of 200mg. There will be no dose escalation. Patients will be treated until disease progression or unacceptable side effects.</description>
    <arm_group_label>MK-2206</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must have metastatic colorectal cancer that has been histologically or&#xD;
             cytologically-confirmed at MSKCC and has failed to respond to appropriate standard&#xD;
             therapy regimens. There is no limit on the number of prior treatment regimens&#xD;
             permitted.&#xD;
&#xD;
          -  Patient is male or female and ≥18 years of age on the day of signing informed consent.&#xD;
&#xD;
          -  Patient must have performance status of 0 or 1 on the ECOG Performance Scale.&#xD;
&#xD;
          -  Patient must have adequate organ function as indicated by the following laboratory&#xD;
             values:&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥1,500 /μL&#xD;
&#xD;
          -  Platelets ≥100,000 /μL&#xD;
&#xD;
          -  Hemoglobin ≥9 g/dL&#xD;
&#xD;
          -  Serum creatinine or calculated creatinine clearance ≤1.5 x upper limit of normal (ULN)&#xD;
             OR ≥60 mL/min for patients with creatinine levels &gt;1.5 x institutional ULN&#xD;
&#xD;
          -  Serum total bilirubin ≤1.5 x ULN OR direct bilirubin ≤ ULN for patients with total&#xD;
             bilirubin levels &gt;1.5 x ULN&#xD;
&#xD;
          -  AST (SGOT) and ALT (SGPT) ≤3 x ULN or ≤5 x ULN in patients with known liver metastasis&#xD;
&#xD;
          -  Prothrombin time (PT)/INR ≤1.5 x ULN&#xD;
&#xD;
          -  Partial thromboplastin time (PTT)≤1.5 x ULN&#xD;
&#xD;
          -  Fasting serum glucose ≤120 mg/dl&#xD;
&#xD;
          -  HBA1C ≤8%&#xD;
&#xD;
          -  Potassium in normal range&#xD;
&#xD;
          -  The patient has a tumor that has wild type KRAS (absence of mutations at codons 12 or&#xD;
             13), and mutant PIK3CA (presence of mutations in exons 20 or 9).&#xD;
&#xD;
          -  Female patient of childbearing potential who are not surgically sterilized must have a&#xD;
             negative serum or urine pregnancy test β-hCG within 72 hours prior to receiving the&#xD;
             first dose of study medication.&#xD;
&#xD;
          -  Patient, or the patient's legal representative, has voluntarily agreed to participate&#xD;
             by giving written informed consent.&#xD;
&#xD;
          -  Patient is able to swallow capsules and has no surgical or anatomical condition that&#xD;
             will preclude the patient from swallowing and absorbing oral medications on an ongoing&#xD;
             basis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who has had chemotherapy, radiotherapy, or biological therapy within 3 weeks&#xD;
             (6 weeks for nitrosoureas or mitomycin C), or who has not recovered from the adverse&#xD;
             events due to previous agents administered more than 4 weeks prior to Study Day 1. If&#xD;
             the patient has residual toxicity from prior treatment, toxicity must be ≤ Grade 1.&#xD;
&#xD;
          -  Patients must be at least 4 weeks post major surgical procedure, and all surgical&#xD;
             wounds must be fully healed.&#xD;
&#xD;
          -  Patient is currently participating or has participated in a study with an&#xD;
             investigational compound or device within 30 days of Study Day 1.&#xD;
&#xD;
          -  Patient has known CNS metastases and/or carcinomatous meningitis.&#xD;
&#xD;
          -  Patient has a primary central nervous system tumor.&#xD;
&#xD;
          -  Patient has known hypersensitivity to the components of study drug or its analogs.&#xD;
&#xD;
          -  Patient has a history or current evidence of clinically significant heart disease&#xD;
             including:&#xD;
&#xD;
          -  Clinically significant congestive heart failure, unstable angina pectoris,&#xD;
&#xD;
          -  Clinically significant cardiac arrhythmia,&#xD;
&#xD;
          -  History or current evidence of a myocardial infarction during the last 6 months,&#xD;
             and/or a current ECG tracing that is abnormal in the opinion of the treating&#xD;
             Investigator,&#xD;
&#xD;
          -  QTc prolongation ≥450 msec (Bazett's Formula), Patient with evidence of clinically&#xD;
             significant bradycardia (HR &lt;50), or a history of clinically significant&#xD;
             bradyarrhythmias such as sick sinus syndrome, 2nd degree AV block (Mobitz Type 2).&#xD;
&#xD;
          -  Patient with uncontrolled hypertension (i.e., &gt; 160/90 mHg SiBP). Patients who are&#xD;
             controlled on antihypertensive medication will be allowed to enter the study.&#xD;
&#xD;
          -  Patient at significant risk for hypokalemia (e.g., patients on high dose diuretics, or&#xD;
             with recurrent diarrhea)&#xD;
&#xD;
          -  Patient with poorly controlled diabetes (HBA1C &gt;8%)&#xD;
&#xD;
          -  Patient has a history or current evidence of any condition, therapy, or lab&#xD;
             abnormality that might confound the results of the study, interfere with the patient's&#xD;
             participation for the full duration of the study, or is not in the best interest of&#xD;
             the patient to participate, in the opinion of the treating Investigator.&#xD;
&#xD;
          -  Patient has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial&#xD;
&#xD;
          -  Patient is, at the time of signing informed consent, a regular user (including&#xD;
             -recreational use‖) of any illicit drugs or had a recent history (within the last&#xD;
             year) of drug or alcohol abuse.&#xD;
&#xD;
          -  Patient is breastfeeding or expecting to conceive or father children within the&#xD;
             projected duration of the study.&#xD;
&#xD;
          -  Patient is known to be Human Immunodeficiency Virus (HIV)-positive&#xD;
&#xD;
          -  Patient has known history of Hepatitis B or C or active Hepatitis A.&#xD;
&#xD;
          -  Patient has symptomatic ascites or pleural effusion. A patient who is clinically&#xD;
             stable following treatment for these conditions is eligible.&#xD;
&#xD;
          -  Patient is receiving treatment with oral corticosteroids (note: inhaled&#xD;
             corticosteroids are permitted).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonard Saltz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>August 20, 2010</study_first_submitted>
  <study_first_submitted_qc>August 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2010</study_first_posted>
  <results_first_submitted>April 7, 2015</results_first_submitted>
  <results_first_submitted_qc>April 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 21, 2015</results_first_posted>
  <last_update_submitted>October 17, 2015</last_update_submitted>
  <last_update_submitted_qc>October 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MK-2206</keyword>
  <keyword>colon</keyword>
  <keyword>rectal</keyword>
  <keyword>10-068</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MK-2206</title>
          <description>This will be a single-arm, phase II study of the AKT inhibitor MK-2206 in patients with KRAS-wild-type, PIK3CA-mutated, colorectal cancer whose tumors have progressed through standard chemotherapy regimens.&#xD;
MK-2206: Patients will receive MK-2206 orally in a once weekly dose of 200mg. There will be no dose escalation. Patients will be treated until disease progression or unacceptable side effects.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MK-2206</title>
          <description>This will be a single-arm, phase II study of the AKT inhibitor MK-2206 in patients with KRAS-wild-type, PIK3CA-mutated, colorectal cancer whose tumors have progressed through standard chemotherapy regimens.&#xD;
MK-2206: Patients will receive MK-2206 orally in a once weekly dose of 200mg. There will be no dose escalation. Patients will be treated until disease progression or unacceptable side effects.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Objective Response Rate (ORR)</title>
        <description>in patients with metastatic colorectal cancer with known PIK3CA mutations and wild type KRAS, to single agent MK-2206. Response and progression will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1)</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MK-2206</title>
            <description>This will be a single-arm, phase II study of the AKT inhibitor MK-2206 in patients with KRAS-wild-type, PIK3CA-mutated, colorectal cancer whose tumors have progressed through standard chemotherapy regimens.&#xD;
MK-2206: Patients will receive MK-2206 orally in a once weekly dose of 200mg. There will be no dose escalation. Patients will be treated until disease progression or unacceptable side effects.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Objective Response Rate (ORR)</title>
          <description>in patients with metastatic colorectal cancer with known PIK3CA mutations and wild type KRAS, to single agent MK-2206. Response and progression will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Progression of Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MK-2206</title>
          <description>This will be a single-arm, phase II study of the AKT inhibitor MK-2206 in patients with KRAS-wild-type, PIK3CA-mutated, colorectal cancer whose tumors have progressed through standard chemotherapy regimens.&#xD;
MK-2206: Patients will receive MK-2206 orally in a once weekly dose of 200mg. There will be no dose escalation. Patients will be treated until disease progression or unacceptable side effects.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>White blood cell descreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Leonard Saltz</name_or_title>
      <organization>Memorial Sloan Kettering Cancer Center</organization>
      <phone>646-888-4286</phone>
      <email>saltzl@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

